Omodanisi Elizabeth I, Aboua Yapo G, Chegou Novel N, Oguntibeju Oluwafemi O
Department of Biomedical Sciences, Nutrition and Chronic Diseases Research Unit, Oxidative Stress Research Centre, Faculty of Health and Wellness Sciences, Cape Peninsula University of Technology, Bellville 7535, South Africa.
Faculty of Health and Wellness Sciences, Cape Peninsula University of Technology, Bellville 7535, South Africa.
Pharmacognosy Res. 2017 Apr-Jun;9(2):182-187. doi: 10.4103/0974-8490.204651.
The number of individuals with diabetes is increasing daily, and diabetes is presently estimated to affect about 422 million adults worldwide. Conventional drugs used to treat diabetes are not without severe side effects, accessibility, and affordability. This study elucidates the potential effects of (MO) leaves extract to manage and treat diabetes induced in male Wistar rats.
Adult male Wistar rats were randomly divided into four groups ( = 12/group): NC - nondiabetic rats (positive control), MO - nondiabetic-treated rats, DM - diabetic rats (negative control), DM + MO - diabetic-treated rats. Hepatic enzymes and biochemical parameters as well as antioxidant capacity and inflammatory cytokine levels were assessed. Levels of low-density lipoprotein, high-density lipoprotein, and total cholesterol were evaluated.
Oral administration of methanolic extract of MO (250 mg/kg) to diabetic rats for 42 days showed a significant reduction in hepatic enzyme markers and normalized lipid profile parameters in the serum compared to normal control group. Treatment also increased the level of antioxidant capacity and alleviated inflammatory biomarkers of the liver. Histology sections of the liver tissue showed protective effect of MO in treated rats.
MO showed hepatoprotective, anti-inflammatory, and lipid-lowering effects against streptozotocin-induced hepatotoxicity. Histological section demonstrated specific alterations in the liver of the diabetic and nondiabetic male Wistar rats while MO treatment revealed improvement in liver alterations.
IL 1: Interleukin 1, IL 6: Interleukin 16, MCP-1: Monocyte chemotactic protein, TNF-α: Tumor Necrotic factor alpha, ROS: Reactive oxygen species, MO: , STZ: Streptozotocin, SRC: Standard rat chow, ALP: Alkaline phosphatase, AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, ORAC: Oxygen radical absorbance capacity, LDL: Low density lipoprotein, HDL: High density lipoprotein, CHOL: Total cholesterol.
糖尿病患者数量与日俱增，目前估计全球约有4.22亿成年人受糖尿病影响。用于治疗糖尿病的传统药物存在严重副作用、可及性和可负担性等问题。本研究阐明了[植物名称]（MO）叶提取物对雄性Wistar大鼠诱导的糖尿病进行管理和治疗的潜在作用。
成年雄性Wistar大鼠随机分为四组（每组n = 12）：NC - 非糖尿病大鼠（阳性对照），MO - 非糖尿病处理大鼠，DM - 糖尿病大鼠（阴性对照），DM + MO - 糖尿病处理大鼠。评估肝酶和生化参数以及抗氧化能力和炎性细胞因子水平。评估低密度脂蛋白、高密度脂蛋白和总胆固醇水平。
与正常对照组相比，给糖尿病大鼠口服MO甲醇提取物（250 mg/kg）42天，血清中肝酶标志物显著降低，脂质谱参数恢复正常。治疗还提高了抗氧化能力水平，减轻了肝脏的炎性生物标志物。肝组织学切片显示MO对处理后的大鼠有保护作用。
MO对链脲佐菌素诱导的肝毒性具有肝保护、抗炎和降血脂作用。组织学切片显示糖尿病和非糖尿病雄性Wistar大鼠肝脏有特定改变，而MO治疗显示肝脏改变有所改善。
IL 1：白细胞介素1，IL 6：白细胞介素16，MCP - 1：单核细胞趋化蛋白，TNF - α：肿瘤坏死因子α，ROS：活性氧，MO：[植物名称]，STZ：链脲佐菌素，SRC：标准大鼠饲料，ALP：碱性磷酸酶，AST：天冬氨酸转氨酶，ALT：丙氨酸转氨酶，ORAC：氧自由基吸收能力，LDL：低密度脂蛋白，HDL：高密度脂蛋白，CHOL：总胆固醇
